Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

Author： Smith Ian  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.130, Iss.1, 2011-11, pp. : 133-143

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

By Lobo Christopher   Lopes Gilberto   Baez Odalys   Castrellon Aurelio   Ferrell Annapoorna   Higgins Connie   Hurley Erin   Hurley Judith   Reis Isildinha   Richman Stephen   Seo Pearl   Silva Orlando   Slingerland Joyce   Tukia Keleni   Welsh Catherine   Glück Stefan  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 427-435

Springer Publishing Company

Access to resources Recommend Favorite

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

By Brufsky Adam  

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 1067-1075

Springer Publishing Company

Access to resources Recommend Favorite

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study

By Aogi Kenjiro   Masuda Norikazu   Ohno Shinji   Oda Takashi   Iwata Hiroji   Kashiwaba Masahiro   Fujiwara Yasuhiro   Kamigaki Shunji   Ito Yoshinori   Ueno Takayuki   Takashima Shigemitsu  

Breast Cancer Research and Treatment, Vol. 129, Iss. 3, 2011-10 ,pp. : 829-838

Springer Publishing Company

Access to resources Recommend Favorite

Vinorelbine, Epirubicin and Fluorouracil as First-Line Therapy in Metastatic Breast Cancer

By Elomaa Inkeri   Joensuu Heikki   Blomqvist Carl  

Acta Oncologica, Vol. 42, Iss. 4, 2003-01 ,pp. : 309-314

Informa Healthcare

Access to resources Recommend Favorite

Anastrozole (Arimidex(TM)) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

By Nabholtz J.M.   Bonneterre J.   Buzdar A.   Robertson J.F.R.   Thurlimann B.   for the Arimidex Writing Committee on behalf of the Investigators  

European Journal of Cancer, Vol. 39, Iss. 12, 2003-08 ,pp. : 1684-1689

Elsevier

Access to resources Recommend Favorite